Upload File

The top documents tagged [median pfs]

ASCO - Gastrointestinal Cancers Symposium Orlando (FL), 25-27 January 2008 First-line Irinotecan, Oxaliplatin and Infusional 5FU/LV (FOLFOXIRI) in combination
ASCO - Gastrointestinal Cancers Symposium Orlando (FL), 25-27 January 2008 First-line Irinotecan, Oxaliplatin and Infusional 5FU/LV (FOLFOXIRI) in combination
213 views
Clinical Case Nº2 Dr. Javier Martín-Broto. Case description 49-year-old man 1 st symptom/sign: Mild pain in right buttock 1 st diagnosis: Core-biopsy:
Clinical Case Nº2 Dr. Javier Martín-Broto. Case description 49-year-old man 1 st symptom/sign: Mild pain in right buttock 1 st diagnosis: Core-biopsy:
214 views
Novel Agents for Indolent Lymphoma and Mantle Cell Lymphoma Stephen Ansell, MD, PhD Mayo Clinic
Novel Agents for Indolent Lymphoma and Mantle Cell Lymphoma Stephen Ansell, MD, PhD Mayo Clinic
219 views
1 New Developments in the Management of Advanced Breast Cancer Supported by an educational grant from Roche Laboratories Including Updates from ASCO 2007
1 New Developments in the Management of Advanced Breast Cancer Supported by an educational grant from Roche Laboratories Including Updates from ASCO 2007
216 views
A randomized phase III study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localized unresectable pancreatic
A randomized phase III study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localized unresectable pancreatic
214 views
Results of a Randomized Phase III Trial (MPACT) of Weekly nab-Paclitaxel Plus Gemcitabine vs Gemcitabine Alone for Patients With Metastatic Adenocarcinoma
Results of a Randomized Phase III Trial (MPACT) of Weekly nab-Paclitaxel Plus Gemcitabine vs Gemcitabine Alone for Patients With Metastatic Adenocarcinoma
219 views
Colorectal Cancer Poster Discussion Discussion of Posters #17 - 25 Wells Messersmith, MD, FACP Director, GI Medical Oncology Program Leader, Developmental
Colorectal Cancer Poster Discussion Discussion of Posters #17 - 25 Wells Messersmith, MD, FACP Director, GI Medical Oncology Program Leader, Developmental
216 views
Which difference should we target?
Which difference should we target?
32 views
The Bruton’s Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Promotes High Response Rate, Durable Remissions, and is Tolerable in Treatment- Naïve
The Bruton’s Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Promotes High Response Rate, Durable Remissions, and is Tolerable in Treatment- Naïve
212 views
Novel Agents for Indolent L ymphoma and Mantle Cell Lymphoma
Novel Agents for Indolent L ymphoma and Mantle Cell Lymphoma
19 views
Neoadjuvant followed by interval cytoreduction Francesco Fanfani Gynecologic Oncology Dpt. Obstetrics & Gynecology Catholic University - Rome francesco.fanfani@rm.unicatt.it
Neoadjuvant followed by interval cytoreduction Francesco Fanfani Gynecologic Oncology Dpt. Obstetrics & Gynecology Catholic University - Rome [email protected]
221 views
1 Paolo G. Casali, John Zalcberg, Jaap Verweij, Axel Le Cesne, Peter Reichardt, Jean-Yves Blay, Lars Lindner, Ian R. Judson, Elena Fumagalli, Pancras Hogendoorn,
1 Paolo G. Casali, John Zalcberg, Jaap Verweij, Axel Le Cesne, Peter Reichardt, Jean-Yves Blay, Lars Lindner, Ian R. Judson, Elena Fumagalli, Pancras Hogendoorn,
213 views